BiotechTube
Allodynic Therapeutics

Allodynic Therapeutics

Boston, United States· Est.
allodynic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Allodynic Therapeutics is pioneering a non-opioid approach to treating neuropathic pain and migraine with its naltrexone-acetaminophen combination. The company has generated promising data from four investigator-initiated Phase 2 trials and is advancing into a formal Phase 2 study for acute migraine. By targeting the Toll-Like Receptor 4 (TLR4) and COX-2 pathways, the combination aims to address a significant unmet need in pain management, potentially offering a safer alternative to opioids and tapping into a large market of millions of patients in the U.S.

MigraineNeuropathic PainChronic Pain

Technology Platform

Novel fixed-dose combination of low-dose naltrexone and acetaminophen, targeting TLR4 and COX-2 pathways for synergistic, multi-mechanistic pain relief.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The combination addresses a massive unmet need for non-opioid pain therapies in a market of tens of millions of migraine and neuropathic pain patients.
Leveraging two well-known drugs could accelerate physician adoption and pave a potential path to an over-the-counter product.

Risk Factors

Clinical success depends on validating early, small-scale trial results in larger, controlled studies.
As a small, pre-revenue private company, it faces significant financing and execution risks in a highly competitive therapeutic area.

Competitive Landscape

Competes in the crowded migraine market against triptans, gepants, and CGRP monoclonal antibodies, and in neuropathic pain against gabapentinoids, SNRIs, and opioids. Differentiation hinges on demonstrating synergistic efficacy, a novel upstream mechanism, and a superior safety profile versus opioids.

More companies in Small Molecule Drugs →More companies in United States →